

Supplemental Material to:



A. Kathleen McClendon, Jeffry L. Dean, Dayana B. Rivadeneira, Justine E. Yu, Christopher A. Reed, Erhe Gao, John L. Farber, Thomas Force, Walter J. Koch and Erik S. Knudsen


CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy


2012; 11(14)

<http://dx.doi.org/10.4161/cc.21127>

<http://www.landesbioscience.com/journals/cc/article/21127>

A**B**





Supplementary Figure S1. A, representative flow cytometry traces of Hs578T cells treated with vehicle (Control), PD-0332991 (PD), and/or doxorubicin (DOX) for 24h are shown. B, cells were treated for 24h, and total protein lysates were immunoblotted as indicated.

Supplementary Figure S2. Representative flow cytometry traces of MDA-MB-231 miRB cells treated with vehicle (Control), PD-0332991 (PD), and/or doxorubicin (DOX) for 24h are shown, and percentage of BrdU-positive cells (left) or Sub-G1 cell populations (right) was quantified (**p=0.0008).

Supplementary Figure S3. Representative images of BrdU staining in MDA-MB-231 xenograft tumors treated with vehicle (Control), PD-0332991 (PD), and/or doxorubicin (DOX) are shown, and percentage of BrdU-positive cells was quantified (*p=0.04, ***p<0.0005).